Premium
MATURE RESULTS FROM A PHASE II TRIAL OF BRENTUXIMAB VEDOTIN PLUS ADRIAMYCIN AND DACARBAZINE WITHOUT RADIATION IN NON‐BULKY LIMITED STAGE CLASSICAL HODGKIN LYMPHOMA
Author(s) -
Abramson J. S.,
Bengston E. M.,
Redd R.,
Barnes J. A.,
Takvorian T.,
Sokol L.,
Lansigan F.,
Armand P.,
Shah B.,
Jacobsen E.,
Martignetti R.,
Turba E.,
Metzler S. R.,
Patterson V.,
LaCasce A. S.,
Bello C. M.
Publication year - 2021
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.110_2880
Subject(s) - medicine , dacarbazine , brentuximab vedotin , abvd , nuclear medicine , gastroenterology , vinblastine , bleomycin , phases of clinical research , clinical endpoint , oncology , surgery , urology , lymphoma , toxicity , hodgkin lymphoma , chemotherapy , clinical trial , vincristine , cyclophosphamide